

	Study Number: D8480C00067	<i>Confidential Document</i>
		Trial Master File Zone: Trial Management Artifact: 1.1.10

Title/Reference: A randomised, double-blind, phase III efficacy and safety study of cediranib (RECENTIN) when added to cisplatin plus a fluoropyrimidine, compared with cisplatin plus a fluoropyrimidine alone, in patients with previously untreated, locally advanced or metastatic, unresectable Gastric Cancer (GC)

Topic: Results not posted on the EudraCT registry.

Summary: The above mentioned study has been submitted to the authorities, however the study was stopped without any patients being recruited, therefore results will not be posted in the EudraCT registry.

██████████, Sr GPD

████████████████████
 Full Name, Position

 Date